


# Journal Pre-proof



International prevalence patterns of low eGFR in adults aged 18-60 without traditional risk factors from a population-based cross-sectional disadvantaged populations eGFR epidemiology (DEGREE) study.

Charlotte E. Rutter, Mary Njoroge, Phil Cooper, Prabhakaran Dorairaj, Vivekanand Jha, Prabhdeep Kaur, Sailesh Mohan, Ravi Raju Tatapudi, Annibale Biggeri, Peter Rohloff, Michelle H. Hathaway, Amelia Crampin, Meghnath Dhimal, Anil Poudyal, Antonio Bernabe-Ortiz, Cristina O'Callaghan-Gordo, Pubudu Chulasiri, Nalika Gunawardena, Thilanga Ruwanpathirana, S.C. Wickramasinghe, Sameera Senanayake, Chagriya Kitiyakara, Marvin Gonzalez-Quiroz, Sandra Cortés, Kristina Jakobsson, Ricardo Correa-Rotter, Jason Glaser, Ajay Singh, Sophie Hamilton, Devaki Nair, Aurora Aragón, Dorothea Nitsch, Steven Robertson, Ben Caplin, Neil Pearce, the DEGREE Study Group

PII: S0085-2538(24)00910-4

DOI: <https://doi.org/10.1016/j.kint.2024.11.028>

Reference: KINT 4069

To appear in: *Kidney International*

Received Date: 26 June 2024

Revised Date: 29 October 2024

Accepted Date: 22 November 2024

Please cite this article as: Rutter CE, Njoroge M, Cooper P, Dorairaj P, Jha V, Kaur P, Mohan S, Tatapudi RR, Biggeri A, Rohloff P, Hathaway MH, Crampin A, Dhimal M, Poudyal A, Bernabe-Ortiz A, O'Callaghan-Gordo C, Chulasiri P, Gunawardena N, Ruwanpathirana T, Wickramasinghe S, Senanayake S, Kitiyakara C, Gonzalez-Quiroz M, Cortés S, Jakobsson K, Correa-Rotter R, Glaser J, Singh A, Hamilton S, Nair D, Aragón A, Nitsch D, Robertson S, Caplin B, Pearce N, the DEGREE Study Group, International prevalence patterns of low eGFR in adults aged 18-60 without traditional risk factors from a population-based cross-sectional disadvantaged populations eGFR epidemiology (DEGREE) study., *Kidney International* (2025), doi: <https://doi.org/10.1016/j.kint.2024.11.028>.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of

record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Copyright © 2024, Published by Elsevier, Inc., on behalf of the International Society of Nephrology.

# International prevalence patterns of low eGFR in rural women and men with traditional risk factors from a population-based cross-sectional disadvantaged populations eGFR epidemiology (DEGREE) study.

Journal Pre-proof

**kidney**  
INTERNATIONAL


**ISN**  
INTERNATIONAL SOCIETY  
OF NEPHROLOGY

## Sample details

- 19 studies across 43 areas in 14 countries



- Data collected between 2007-23



- Adults aged 18-60 years from the general population



- 60 964 participants with complete data

## Methods

Age-standardised prevalence of eGFR<60mL/min/1.73m<sup>2</sup> in people without traditional risk factors for chronic kidney disease (CKD)

- No hypertension, diabetes or heavy proteinuria



- Stratified by sex and area type (urban/rural)

- CKD-EPI 2009 creatinine-based eGFR equation (without race), with sensitivity analyses for other equations


## Findings

The highest prevalence was seen in men in rural areas of Nicaragua (14%) and Uddanam, India (14%). Prevalence was also high for rural men in parts of Sri Lanka (8%)

For women, prevalence was high in some rural areas of Ecuador (6%) and Uddanam, India (up to 8%)

Sensitivity analyses did not substantially change the findings

## Prevalence of low eGFR in rural women (top) and rural men (bottom)



Rutter C, Njoroge M, et al., 2024

**CONCLUSION:** The available evidence supports a high general-population burden of CKD of unknown cause in multiple areas within Central America and South Asia.

**[QUERY TO AUTHOR: title and abstract rewritten by Editorial Office – not subject to change]**

**International prevalence patterns of low eGFR in adults aged 18-60 without traditional risk factors from a population-based cross-sectional disadvantaged populations eGFR epidemiology (DEGREE) study.**

Charlotte E Rutter<sup>1\*</sup>, Mary Njoroge<sup>1</sup>, Phil Cooper<sup>2</sup>, Prabhakaran Dorairaj<sup>3</sup>, Vivekanand Jha<sup>4</sup>, Prabhdeep Kaur<sup>5</sup>, Suresh Mohan<sup>3</sup>, Ravi Raju Tatapudi<sup>6</sup>, Annibale Biggeri<sup>7</sup>, Peter Rohloff<sup>8</sup>, Michelle H Hathaway<sup>9</sup>, Amelia Crampin<sup>10</sup>, Meghnath Dhimal<sup>11</sup>, Anil Poudyal<sup>11</sup>, Antonio Bernabe-Ortiz<sup>12</sup>, Cristina O'Callaghan-Gordo<sup>13</sup>, Pubudu Chulasiri<sup>14</sup>, Nalika Gunawardena<sup>15</sup>, Thilanga Ruwanpathirana<sup>14</sup>, SC Wickramasinghe<sup>14</sup>, Sameera Senanayake<sup>16</sup>, Chagriya Kitiyakara<sup>17</sup>, Marvin Gonzalez-Quiroz<sup>18-20</sup>, Sandra Cortés<sup>21</sup>, Kristina Jakobsson<sup>22,23</sup>, Ricardo Correa-Rotter<sup>24</sup>, Jason Glaser<sup>23</sup>, Ajay Singh<sup>25</sup>, Sophie Hamilton<sup>26</sup>, Devaki Nair<sup>19,27</sup>, Aurora Aragón<sup>20</sup>, Dorothea Nitsch<sup>28</sup>, Steven Robertson<sup>29</sup>, Ben Caplin<sup>19</sup>, Neil Pearce<sup>1</sup> and the DEGREE Study Group<sup>a</sup>

[1] Department of Medical Statistics, London School of Hygiene & Tropical Medicine, London, UK

[2] Institute of Infection and Immunity, St George's University of London, UK; School of Medicine, Universidad Internacional del Ecuador, Quito, Ecuador

[3] Public Health Foundation of India, New Delhi, India

[4] George Institute for Global Health, UNSW, New Delhi, India; School of Public Health, Imperial College, London, UK; Prasanna School of Public Health, Manipal Academy of Higher Education, Manipal, India

[5] Indian Institute of Science, Bengaluru, India

[6] The Apollo University, Chittoor, Andhra Pradesh, India

[7] Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padua, Italy

[8] Center for Indigenous Health Research, Maya Health Alliance, Wuqu' Kawoq, Guatemala

[9] Division of Environmental and Occupational Health Sciences, School of Public Health, University of Illinois Chicago, USA

[10] Malawi Epidemiology and Intervention Research Unit (MEIRU), Malawi; University of Glasgow, UK

[11] Nepal Health Research Council, Kathmandu, Nepal

[12] CRONICAS Center of Excellence in Chronic Diseases, Universidad Peruana Cayetano Heredia, Peru

[13] Faculty of Health Sciences, Universitat Oberta de Catalunya, Barcelona, Spain; ISGlobal, Barcelona, Spain; Universitat Pompeu Fabra, Barcelona, Spain; CIBER Epidemiología y Salud Pública, Madrid, Spain

[14] Ministry of Health, Sri Lanka

[15] WHO Regional Office, New Delhi, India

[16] Duke-NUS Medical School, Singapore

[17] Faculty of Medicine Ramathibodi Hospital, Mahidol University, Thailand

[18] Department of Environmental and Occupational Health, UT School of Public Health San Antonio, The University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA

[19] Centre for Kidney and Bladder Health, University College London, London, UK

[20] Wuqu' Kawoq Maya Health Alliance, Chimaltenango, Guatemala

[21] Advanced Center for Chronic Diseases (ACCDiS), Faculty of Medicine, Pontifical Catholic University of Chile, Santiago, Chile

[22] School of Public Health and Community Medicine, University of Gothenburg, Sweden

[23] La Isla Network, Ada, Michigan, USA

[24] Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico; National Autonomous University of Mexico, Mexico

[25] Harvard University, USA

[26] Department of Epidemiology and Biostatistics, Imperial College London, London, UK

[27] Department of Clinical Biochemistry, Royal Free Hospital, London, UK; Health Services Laboratories, London, UK

[28] Department of Non-communicable Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UK

[29] Clinical Trials Unit, London School of Hygiene & Tropical Medicine, London, UK

<sup>a</sup> Study group listed at the end of the paper

**\*Corresponding author:** Charlotte Rutter, Department of Medical Statistics, LSHTM, Keppel St, London WC1E 7HT  
[Charlotte.Rutter1@lshtm.ac.uk](mailto:Charlotte.Rutter1@lshtm.ac.uk) ORCID 0000-0002-9823-7932

**Article type:** Original paper, clinical investigation

**Word count:** (abstract) 250 [250 max]; (main body) 4036 [4000 max]

## **Abstract**

The disadvantaged populations eGFR (estimated glomerular filtration rate) epidemiology (DEGREE) study was designed to gain insight into the burden of chronic kidney disease (CKD) of undetermined cause (CKDu) using standard protocols to estimate the general-population prevalence of low eGFR internationally. Therefore, we estimated the age-standardized prevalence of eGFR under 60 ml/min per 1.73m<sup>2</sup> in adults aged 18-60, excluding participants with commonly known causes of CKD; an ACR (albumin/creatinine ratio) over 300 mg/g or equivalent, or self-reported or measured (HT) hypertension or (DM) diabetes mellitus, stratified by sex and location. We included population-representative surveys conducted around the world that were either designed to estimate CKDu burden or were re-analyses of large surveys. There were 60,964 participants from 43 areas across 14 countries, with data collected 2007- 2023. The highest prevalence was seen in rural men in Uddanam, India (14%) and Northwest Nicaragua (14%). Prevalence above 5% was generally only observed in rural men, with exceptions for rural women in Ecuador (6%) and parts of Uddanam (6–8%), and for urban men in Leon, Nicaragua (7%). Outside of Central America and South Asia, prevalence was below 2%. Our observations represent the first attempts to estimate the prevalence of eGFR under 60 without commonly known causes of CKD around the world, as an estimate of CKDu burden, and provide a starting point for global monitoring. It is not yet clear what drives the differences, but available evidence supports a high general-population burden of CKDu in multiple areas within Central America and South Asia, although the possibility that unidentified clusters of disease may exist elsewhere cannot be excluded.

**Keywords:** CKDu, CKDnt, MeN, CINA, eGFR, prevalence

### **Lay summary**

In recent decades there have been reports of epidemics of chronic kidney disease (CKD) killing young men in Central America and South Asia. These cases do not involve the commonly known causes of CKD such as diabetes, so they are known as CKD of unknown cause (CKDu). To understand the size and extent of the problem around the world, we included data from studies that measured kidney function from 43 areas across 14 countries (60,964 people). We calculated the prevalence of poor kidney function in working-age men and women in urban and rural areas, in those without indicators of the commonly known causes of CKD. The most affected groups were rural men in Uddanam, India (14%), and Northwest Nicaragua (14%). Low prevalence (<2%) was seen in included areas outside of Central America and South Asia. These findings are important to direct future research, give clues to the possible causes of CKDu, and as a starting point for global monitoring.

## Introduction

Globally, chronic kidney disease (CKD) is most commonly associated with diabetes, hypertension, other cardiovascular diseases, glomerulonephritis, genetic or congenital abnormalities, or urological diseases. However, there is an increasing recognition of forms of progressive CKD which are not associated with these known risk factors, and which are mostly affecting the working-age populations in low- and middle-income countries (LMICs).<sup>1,2</sup> This clinical syndrome has been termed CKD of undetermined cause (CKDu); other names used include CKD of non-traditional cause (CKDnt), Mesoamerican Nephropathy (MeN), Uddanam nephropathy, and chronic interstitial nephritis of agricultural communities (CINAC). Over the last few decades, clusters of CKDu have been reported in Central America,<sup>3</sup> Mexico,<sup>4</sup> India,<sup>5</sup> and Sri Lanka.<sup>6</sup> Other reports have suggested that similar patterns may be occurring in other regions of the world, but it is only recently that efforts have increased to undertake comparable population surveys in working-age populations elsewhere in LMICs.

Perhaps the most clearly established risk factor/epidemiological association in both Central America and South Asia, is that CKDu is more common among men engaged in manual labour in hot climates, particularly in agricultural communities.<sup>7</sup> In Central America, CKDu occurs frequently in sugar cane workers but also in other occupational groups, including other agricultural workers, fishermen, miners, brick kiln and construction workers<sup>8</sup>; it also occurs, albeit at a lower frequency, in women, most of whom have not reported working in agriculture. In common with historical endemic kidney diseases such as Balkan Nephropathy,<sup>9</sup> the absence of substantial albuminuria or haematuria, alongside geographical clustering, supports a primarily tubular-interstitial disease, and potentially a causal role for environmental exposure(s). Many specific potential causes related to agriculture have been suggested for CKDu. Heat/dehydration, pesticides, and heavy metals are the main hypotheses proposed for Central America, whereas in South Asia the emphasis has been on the possible roles of water contamination by metals and/or pesticides.<sup>10-12</sup>

In the past, international comparisons have played a key role in identifying possible causes of chronic disease.<sup>13</sup> For example, many of the discoveries on the causes of cancer (e.g., human papilloma virus and cervical cancer) have their origins, directly or indirectly, in the systematic international comparisons of cancer incidence conducted in the 1950s and 1960s. Hypotheses generated from these studies were investigated in more depth in further studies.<sup>14</sup> A more recent example is the International Study of Asthma and Allergies in Childhood (ISAAC), a standardised protocol to estimate the prevalence of asthma internationally,<sup>15,16</sup> which has now evolved into the Global Asthma Network.<sup>17,18</sup> This has led to a greater understanding of the possible causes of asthma globally, as well as the creation of a large international network of researchers.

We have proposed a similar approach involving a simple and practical protocol to describe distributions of kidney function, using the estimated glomerular filtration rate (eGFR), in disadvantaged communities globally: the disadvantaged populations eGFR epidemiology (DEGREE) study. The DEGREE protocol was explicitly developed for general population-based surveys.<sup>19</sup> It was noted that the same methodology could be used in other contexts (e.g., workforce surveys), but the current paper focusses on population surveys.

As the causes of CKDu are unknown, diagnosis is often made by exclusion of known causes of kidney disease. The DEGREE protocol uses pragmatic criteria (absence of diabetes, hypertension, or heavy proteinuria) to estimate the prevalence of low eGFR unrelated to known causes of kidney disease (with the latter features being common in most forms of glomerular diseases). This enables standardised comparisons across multiple centres and is intended to identify population patterns, rather than diagnose CKDu in individuals.

We here report the first findings from the DEGREE study, involving 60,964 participants with complete data from 19 studies across 43 areas in 14 countries, with date of data collection varying by study between 2007 and 2023 (**Table 1**). These are primarily in LMICs, plus one study in rural



Italy, another in Chile, and publicly available data from England and the United States as reference points for comparison.

## Methods

The DEGREE collaboration aims to gain insight into the burden of CKDu by using standard protocols to estimate the prevalence of low eGFR in population-representative surveys; the detailed rationale and methods have previously been published.<sup>19</sup> Here we use the term CKDu to describe the endemic kidney disease of unknown cause occurring at epidemic levels in geographic clusters (i.e., the disease(s) also termed Mesoamerican nephropathy, Uddanam nephropathy or chronic interstitial nephritis in agricultural communities) rather than all forms of CKD without a diagnosis. Defining CKDu is challenging, both at the individual level, and for epidemiological studies, as there is no gold-standard diagnostic test, and diagnosis currently relies on the exclusion of known causes of kidney disease, with only a small number of cases fully documented as tubulointerstitial disease with a kidney biopsy. For these international comparisons of general population prevalence, we have used a pragmatic definition of an eGFR  $<60$  ml/min per  $1.73\text{m}^2$  in the absence of diabetes, hypertension, and heavy proteinuria in the working-age population as a surrogate indicator of CKDu burden.

Another important consideration when conducting international comparisons of eGFR is analytical variability in laboratory assays. In this analysis, all studies used standardised isotopic dilution mass spectrometry (IDMS) referenced creatinine measurements, which should minimise this problem, although inter-laboratory and time-dependent variation are still present.<sup>36</sup> Note that we do not have written confirmation for Nicaragua 1, but this was conducted in a Ministry of Health laboratory where IDMS references were being used at that time. Similar quality control methods are not widely used for cystatin C determination. For our studies, the cystatin C measurements for India, Malawi and Peru were all standardised to a central reference laboratory, but the cystatin C data from Kenya were not standardised.

There were 11 studies formally registered with DEGREE that agreed to conduct population surveys using the DEGREE protocol. Of these, 10 provided data for this analysis. In addition, we identified 11 other studies, using methodology compatible with the DEGREE protocol, that had already been conducted in areas with reported high CKDu prevalence or in settings with proposed CKDu risk-factors. The organisers of these other studies were therefore invited to contribute their data to the joint analyses, of whom seven responded positively and provided data. The studies varied both in the size of the sample and the size of the source population, from focused surveys of specific communities to regional or national surveillance projects (details in **Table 1**). However, all surveyed the general population of the relevant area (most using either simple random sampling or multi-stage cluster random sampling, see Supplementary Table S1). Of the 17 collaborating studies, seven provided us with their data in tabular form, whereas 10 provided us with individual level datasets to create the relevant tables (see Supplementary Table S1). Additionally, publicly available data from health surveys in England<sup>22</sup> and the USA<sup>35</sup> were obtained to provide reference data from high-income countries. Thus, a total of 19 studies were involved in the current analysis, each reporting data from one or more separately sampled areas.

Populations vary in their age-distribution, and to make our country-comparisons fair, the main outcome was the age-standardised prevalence of eGFR<60 ml/min per 1.73m<sup>2</sup> (using the WHO global standard population<sup>37</sup>) in those without hypertension, diabetes, and heavy proteinuria (eGFR<60<sub>[absent HT,DM,high ACR]</sub>), for working-age adults, stratified by rural-urban classification (except the USA where this was not available) and sex (details in Supplementary Text S1).

We also calculated the overall prevalence of eGFR<60 ml/min per 1.73m<sup>2</sup> without excluding the population with hypertension, diabetes, or heavy proteinuria (eGFR<60), for comparison. Confidence intervals were calculated for all standardised prevalence estimates.

Except where indicated in Supplementary Table S1, eGFR was calculated using the creatinine-based CKD-EPI 2009 equation<sup>38</sup> but without race adjustment; heavy proteinuria was defined by an albumin-

to-creatinine ratio (ACR) of >300 mg/g or  $\geq$ ++ when studies used dipstick urinalysis; diabetes was determined by self-report or HbA1c  $\geq$ 6.5%; and hypertension was determined by self-report, treatment, systolic blood pressure  $\geq$ 140 mm Hg, or diastolic blood pressure  $\geq$ 90 mm Hg.

To better understand any selection bias impacting the prevalence estimates, we compared the prevalence of eGFR<60 in the whole available sample to those with complete data for hypertension, diabetes, and proteinuria (before making any exclusions).

Similar analyses were completed using secondary outcomes with a cut-off of 90 ml/min per  $1.73\text{m}^2$  (eGFR<90 and eGFR<90<sub>[absent HT,DM,high ACR]</sub>) to help understand the distribution of low to moderate kidney function and whether the patterns follow or differ to that of low eGFR.

The main analysis used eGFR calculated from serum creatinine, but in a subset, data were available to calculate eGFR using serum cystatin C. Within this subset we compared the results from the original creatinine-based equation to the CKD-EPI 2012 cystatin C only equation and combined creatinine and cystatin C equation.<sup>39</sup> We also calculated Lin's concordance correlation coefficient on the individual eGFR data to compare the different measurements.

Prevalence estimates of the main outcome (eGFR<60<sub>[absent HT,DM,high ACR]</sub>) were plotted on international maps, categorised into low (<2%), moderate (2%–5%) and high (>5%), to enable visualisation of geographical differences.

Finally, we undertook some sensitivity and other supplementary analyses as follows:

1. Where individual-level data were available, we ran a sensitivity analysis using age-dependent cut-offs of eGFR from a 2020 paper by Jonsson.<sup>40</sup>
2. We ran another sensitivity analysis to consider different eGFR equations using serum creatinine, including CKD-EPI 2021 and CKD MDRD, where it was possible to calculate.

3. We looked for any associations between the main prevalence outcome and study/sample characteristics, including response rate, the proportion of males in the sample, and date of the study.

Data were analysed using Stata version 17<sup>41</sup> and maps were created using the free open-source QGIS software.<sup>42</sup>

## Results

The characteristics of the 19 studies and 43 areas, including study rationale, response rates and the size of representative populations are shown in **Table 1** (with location maps in Supplementary Figure S1). Most studies were in tropical regions and LMICs. The studies were undertaken at different times, ranging from 2007 in Leon and Chinandega, Nicaragua to 2023 in Molina, Chile. The proportion of men in each sample varied from 24%–53% with a median of 43%. The median age varied from 28 years (IQR=[22, 38]) in Lilongwe, Malawi to 53 [48, 57] in Molina, Chile. Stratifying by sex and using age-standardisation mitigates these differences to allow for valid comparisons.

Response rates were mainly high (above 75% and up to 98%), with the exceptions of the high-income reference datasets (England 59%, USA 49%) and the Ecuador (61%), Guatemala (58% and 69%) and Malawi (66% and 37%) studies plus one area of Thailand (South 73%).

Overall, 2015 (3.2%) participants were missing data on hypertension, diabetes, or proteinuria, used in the exclusions, leaving a total sample size of 60,964. The study with the most missing data on these factors was Nepal, where 874 participants (8.9%) had missing data. For all areas considered, estimates of the prevalence of eGFR<60 in the total sample were very similar to those in the sample with complete data (Supplementary Table S2).

There were 22,255 (36.5%) participants identified as having one or more conditions of hypertension, diabetes, and heavy proteinuria, leaving a sample size of 38,709 for the restricted analyses. The

proportion of participants with these conditions varied greatly by area, ranging from about 16% in two Kenyan areas to over 50% in four areas of India. Some of this difference could be explained by the age structure of the samples (as this is before age-standardisation) (**Tables 1 and 2**).

The age-standardised prevalence estimates of  $eGFR < 60_{[absent\ HT, DM, high\ ACR]}$  stratified by area, sex, and rural-urban classification are shown in **Table 2** and **Figures 1-4**. For men, standardised prevalence estimates of  $eGFR < 60_{[absent\ HT, DM, high\ ACR]}$  were highest in rural areas of Uddanam, India (up to 13.7%, 95% confidence interval (CI) [4.8%, 22.6%]) and areas in northwest Nicaragua (up to 13.6% [6.3%, 20.9%]). Of the other areas considered, prevalence in rural males was low (<2%) in Nepal and some other areas of India and in all areas outside of Central America and South Asia; including Kenya, Peru, Chile, Malawi, and Thailand. High prevalence (>5%) in men was generally only seen in rural areas, but there was one high prevalence urban area in Leon, Nicaragua, and moderate prevalence in Lilongwe, Malawi. There was one low prevalence (<2%) rural area in Nicaragua that was included because residents mainly worked in the service sector. As expected, the prevalence of  $eGFR < 60_{[absent\ HT, DM, high\ ACR]}$  was low in the USA, England, and Italy.

For women, the prevalence of  $eGFR < 60_{[absent\ HT, DM, high\ ACR]}$  was generally low, except rural women had an 8.0% [2.0%, 14.1%] prevalence in one area of Uddanam and 6.0% [2.2%, 9.7%] in Ecuador. There was a moderately high prevalence (2%–5%) in women in Malawi and urban women in Nepal (**Table 2** and **Figures 1 and 2**).

Standardised prevalence of  $eGFR < 60$  (without exclusions) was generally higher than the standardised prevalence of  $eGFR < 60_{[absent\ HT, DM, high\ ACR]}$  as expected, but followed a similar pattern, being highest in rural Uddanam, India (men up to 18.4%, women up to 11.0%) and rural men in Nicaragua (up to 19.0%) (**Table 2**).

When considering low-moderate eGFR values ( $eGFR < 90_{[absent\ HT, DM, high\ ACR]}$ ), there was great variability of prevalence and much higher prevalences in some areas, even those without a high prevalence of  $eGFR < 60_{[absent\ HT, DM, high\ ACR]}$  such as England (Supplementary Table S3).

Concordance between eGFR measurements in individuals calculated using creatinine alone compared to cystatin C alone and both creatinine and cystatin C can be seen in Supplementary Table S4. The standardised prevalence of  $eGFR < 60_{[absent\ HT, DM, high\ ACR]}$  using cystatin C was substantially higher in Sonipat and Vizag, India compared to using creatinine in both men and women (from 12.1%–21.3% versus 0.0%–6.7%). The equation using both creatinine and cystatin also gave higher prevalence but at a much closer level (0.4%–10.1%). In two areas of Kenya, there was zero prevalence with the creatinine equation and the creatinine-cystatin equation, but prevalences of 10.4% and 14.3% in women and 3.6% and 0% in men using cystatin alone, although numbers with cystatin C measures were small. Estimates of the prevalence of  $eGFR < 60_{[absent\ HT, DM, high\ ACR]}$  did not differ substantially by measure in Peru, and were lower in Malawi and England when using cystatin C. Similar patterns were seen for  $eGFR < 60$  (without exclusions). (Table 3 and Supplementary Table S5)

Results from the sensitivity analyses can be found in Supplementary Text S2.

## Discussion

Our findings are consistent with, and build upon, previous evidence, suggesting a high general population burden of impaired kidney function in the absence of traditional risk factors in areas of Central America, and South Asia (Sri Lanka and South India). Applying the same definition to reference populations from high-income countries, as expected, demonstrated a low prevalence. A key strength of the approach used is that it only depends on eGFR and is independent of the presence or absence of a kidney disease diagnosis. This is of critical importance as such diagnoses are highly dependent on access to nephrology care, which is extremely limited in many CKDu

affected regions, making comparisons that rely on 'absence of diagnosis' across regions almost impossible to interpret.

#### *Summary of findings and comparisons to existing literature*

In India, studies with a range of sizes of source populations (from thousands to millions) and conducted both with the specific aim of quantifying CKDu prevalence and as part of non-CKDu focused non-communicable disease surveillance surveys, demonstrated similar patterns. That is of a high general population burden of disease in areas of rural coastal Uddanam, but not in urban areas of South India or urban or rural areas in northern India. Interestingly, in the rural coastal areas of Uddanam, where women may also work in the agricultural sector, the prevalence of  $eGFR < 60_{[absent HT, DM, high ACR]}$  in women approached or exceeded that in men in some study sites. In the Anuradhapura district of Sri Lanka, we observed a high prevalence among men in two out of five rural communities (with moderate prevalence in another two) with small source populations. However, these communities were specifically selected on the basis of clinical data on CKDu burden, thus, it is impossible to make generalisations as to the burden of disease across the wider district.

In northwest Nicaragua, similar to India, data from both a study with a small source population (of thousands) focused on reported high CKDu communities, and a non-CKDu focused non-communicable disease surveillance survey with a larger source population (hundreds of thousands), demonstrated similar patterns with a high prevalence of  $eGFR < 60_{[absent HT, DM, high ACR]}$  in men.

Unusually, there was also a high prevalence of this outcome in the urban population in the latter study, although it is possible that those living in this urban area may still work in agricultural settings.

Unfortunately, we were unable to include data from a national survey conducted in El-Salvador (source populations of millions), but this study used similar definitions and reported a prevalence well above reference levels among rural males.<sup>43</sup> The single study in Guatemala also showed moderate levels of  $eGFR < 60_{[absent HT, DM, high ACR]}$  in males living in the lowland population sample but low levels in the high-altitude sample.

Many of the studies were conducted using the DEGREE protocol specifically to explore whether there was a burden of CKDu in areas with similar profiles to those seen in areas reported to be affected by a high disease burden. However, the prevalence of  $eGFR < 60_{[absent\ HT, DM, high\ ACR]}$  in rural males was low in Tumbes, Peru (Pacific Coast Latin America, subtropical climate, agricultural), Manabi Province, Ecuador (Pacific Coast Latin America, tropical, agricultural), Karonga District, Malawi (subtropical, agricultural) and Muhoroni Sub-County, Kenya (subtropical, agricultural [specifically sugarcane]). Interestingly, we did identify high prevalence of  $eGFR < 60_{[absent\ HT, DM, high\ ACR]}$  amongst women in Ecuador, and moderately high amongst urban males and both urban and rural women in Malawi, patterns which are not considered typical of CKDu in Central America and South Asia. The relevance of these latter findings remains unclear.

The Thailand study was a re-analysis of a national population survey with a large source population (millions). Sub-populations with a higher prevalence of individuals meeting the case definition (i.e., localised “hot spots”) may be obscured in the larger sampling frames. However, (i) the prevalence of  $eGFR < 60_{[absent\ HT, DM, high\ ACR]}$  is lower than that in the high-income reference populations, and (ii), the source populations of the individual regions in the Thai study are comparable to other large population surveys (included and not included<sup>43</sup> in this analysis). This suggests that the general population burden of  $eGFR < 60_{[absent\ HT, DM, high\ ACR]}$ , is several fold lower in rural regions of Thailand than in the areas most impacted by CKDu in Central America or India. Another population-based study conducted in Northeastern Thailand (not included in this analysis) reported rates of  $eGFR < 60$  ml/min of ~10% (without excluding diabetes, hypertension or heavy proteinuria),<sup>44</sup> but this was almost entirely driven by participants over 60 years of age, and estimates in the working age population were completely consistent with those reported in the analysis included in the current study. The aggregated data from Nepal was derived from a very large source population, and as reports of possible CKDu are mainly focused on returning migrant workers in this country,<sup>45</sup> it would likely not be possible to detect a high burden of  $eGFR < 60_{[absent\ HT, DM, high\ ACR]}$  in this group using our approach.



### *Limitations*

When drawing conclusions about CKDu burden the above findings must be considered in the context of limitations of our approach. The pragmatic definition we have used will of course be prone to misclassification in both directions. For example, the definition we used will lead to the inclusion of a range of non-proteinuric (and moderately-proteinuric, non-hypertensive) chronic kidney diseases of both known (e.g., due to congenital abnormalities, granulomatous, or drug-induced chronic interstitial nephritides) and unknown (but non-CKDu) causes. Furthermore, the absence of confirmatory eGFR measures means a proportion of cases reflect those with acute, rather than chronic, kidney injury. Conversely, some true cases of CKDu were probably excluded, particularly where the disease co-exists with diabetes or hypertension (although this would only have biased the prevalence estimates if the prevalence of CKDu was markedly different in people with these conditions than in those without), or in advanced disease where proteinuria is well described. Given this potential for misclassification, a low disease burden will not be observable using our definitions. Nonetheless, a high general population prevalence of eGFR<60<sub>[absent HT,DM,high ACR]</sub> clearly identifies regions known to be hotspots of CKDu.

The rationale and scale of the studies included in this analysis varied substantially. Some studies were part of large country-wide non-communicable disease surveys, some were specific to kidney disease but covering smaller areas with typical CKDu population characteristics but without previous reports of a high burden of disease, and others were targeted at specific areas chosen on the expectation that the prevalence was high or low. However, all studies were population representative and although response rates varied, this did not appear to be related to the prevalence of the outcome (Supplementary Table S8).

Similarly, working age men tended to be under-represented in most studies. However, this will not affect the prevalence estimates for this group (i.e., the proportion with low eGFR in the working age

men who actually participated), unless specific high-risk subgroups (e.g., men in occupations with high prevalence) are under- or over-represented.

Another important limitation is that the CKD-EPI equation has been reported to substantially overestimate eGFR around the 60 ml/min per 1.73m<sup>2</sup> threshold in Indian<sup>46</sup> and sub-Saharan African<sup>47</sup> populations, and the validity of the equation is unknown in other groups, such as indigenous Americans. We were able to use cystatin C-based equations which have been shown to be more precise<sup>48</sup> to address this issue in a number of the studies included in this analysis. This sub-analysis demonstrated an increased proportion meeting the outcome across all regions in the Indian study, although relative patterns of prevalence were preserved. This confirms the challenges surrounding using GFR estimating equations in the Indian population but does not alter the conclusions around the areas most affected by CKDu. This sub-analysis also demonstrated increases in prevalence of the outcome in the Kenyan study, particularly in women, though numbers with cystatin C testing were small, preventing firm conclusions. The cystatin C analysis did not change the major conclusions in the Malawi or Peru studies.

It is important to highlight that although we report substantial variability in age-standardised eGFR<60<sub>[absent HT,DM,high ACR]</sub> we only aim to describe international patterns in the general population. We identified substantial variability eGFR<60<sub>[absent HT,DM,high ACR]</sub> even between areas within high prevalence regions, and in both Central America<sup>11,49</sup> and South Asia<sup>50</sup> there is evidence supporting an even higher prevalence of CKDu in specific high-risk, i.e., occupational, groups. Therefore, there might be an important burden of CKDu in similar groups located in regions where we have not identified evidence of a high general population prevalence of disease. Only adequately powered, targeted studies in these high-risk populations can address this, and specific studies are therefore needed. Furthermore, other than sex- and urban-rural residence, we have not explored any ecological or individual-level risk factors for eGFR<60<sub>[absent HT,DM,high ACR]</sub>.

Finally, it should be noted that this study was descriptive and intended to identify areas with high burden of disease. It was not intended to identify the causes of CKDu or to explain the observed international patterns. Factors that may affect the international patterns may include differences in exposure to potential risk factors for CKDu (leading hypotheses as to the primary cause of CKDu include occupational heat stress, metal(loid) exposure (particularly in water), and pesticide and particulate matter exposure<sup>1</sup>), differences in the degree of misclassification (e.g., the proportion of non-CKDu causes of low eGFR<sub>[absent HT,DM,high ACR]</sub>) between studies, as well as differences in methodology across the included studies. The patterns we have identified clearly require further research.

### *Conclusion*

The study findings provide useful estimates of population patterns of low eGFR and are of considerable interest. Taken alongside published evidence, the observations from large surveys and smaller studies support a high general-population burden of CKDu in Central America and Uddanam, India, however there is no evidence for a similar population burden of disease from large surveys in other parts of India or in Thailand. There is also evidence from smaller surveys for a substantial burden of disease, in particular communities in the Anuradhapura district of Sri Lanka, again supporting published evidence. Several other regions surveyed, that have superficially similar characteristics to affected areas (i.e., hot, low-income, agricultural settings) did not demonstrate a prevalence of low eGFR consistent with a high general population burden of CKDu.

### **Disclosure**

This work was funded by grants from the UK Colt Foundation (CF/02/18) and the UK Medical Research Council (MR/P02386X/1 and MR/V033743/1).

In addition, individual centres received funding as follows: The study in Chile was supported by the Chilean Agency of Research and Development (ANID), FONDECYT grant 1221680, and FONDAP-

MAUCO grant 1523A0008; The study in Ecuador was supported by Universidad Internacional del Ecuador grant EDM-INV-04-19; The study in Guatemala was supported by NIH Grant NIH/FIC 5R21TW010831; The Indian study in Uddanam was supported by a Grand Challenge Award from the Indian Council of Medical Research and the State Government of Andhra Pradesh; The Sri Lankan study was supported by the National Science Foundation of Sri Lanka (RPHS/2016/CKDu 07), the Ministry of Health, Nutrition and Indigenous Medicine and the World Health Organization Country Office Sri Lanka. The study in Italy was supported by the European Union's Horizon 2020 research and innovation programme grant 824484; The Kenyan study was supported by the National Institute for Occupational Safety and Health (NIOSH), Illinois Education and Research Center (ERC) Pilot Project Research Training Grant (T42/OH008672), Environmental and Occupational Health unrestricted global health research funds, Michael Bruton Workplace Safety Foundation Scholarship (2019), UIC Graduate College Award for Graduate Research (2019), Paul Brandt-Rauf Scholarship in Global Health (2018–19), and Donna Farley Global Health Scholarship (2020–21); The UDAY study in India was supported by an unrestricted educational grant from Eli Lilly and Company under the Lilly NCD Partnership Program. The funding agency had no role in the design, conduct or analysis of the study; The Indian study in Prakasam district was supported by the Indian Council of Medical Research, New Delhi; The earlier Nicaraguan study was supported by the Swedish International Agency for Development Cooperation (Sida), through the SAREC project of Bilateral Research Cooperation with UNAN-León and the Sida-Health supported SALTRA; The later Nicaraguan study was supported by a grant from the Dutch National Postcode Lottery provided funding to Solidaridad covering a proportion of the fieldwork costs and by the La Isla Network. The Thai NHES V study was supported by the Bureau of Policy and Strategy, Ministry of Public Health, Thai Health Promotion Foundation, National Health Security Office, Thailand.

In addition to the funding listed above, author disclosures related to this work are as follows: AB is President of Epidemiologia e Prevenzione, a non-profit social enterprise; PJC has received funding from the National Institute for Health and Care Research (NIHR) (grant 134801); BC has received

grants from Kidney Research UK, the Colt foundation and AstraZeneca, has participated on the board of the AstraZeneca ORTIZ study, and has leadership roles in ISN Consortium of CKDu Collaborators (i3C), ISN Western European Board, Consortium for the Epidemic of Nephropathy in Central America and Mexico (CENCAM), and Kidney Research UK Grants Committee; RCR has received grants from AstraZeneca, Novonordisk, Boehringer Ingelheim, Roche, and Chinook, to his institution, fees for consultancy from AstraZeneca, Novonordisk, Boehringer Ingelheim, Chinook, and Bayer, and honoraria payments from AstraZeneca, Novonordisk, Boehringer Ingelheim, Amgen, and Bayer; SC has received a grant from the NIHR (134801); VJ has received consultancy fees from Bayer, AstraZeneca, Visterra, Chinook, Vera, Biocryst, and Otsuka; DN is the UK Kidney Association Director of Informatics research (unrelated to this work); COCG has received grants from the Universitat Oberta de Catalunya (UOC) and Barcelona Institute for Global Health (ISGlobal); PR received funding from the National Institutes of Health (USA) and is Chief Science Officer of the Maya Health Alliance Guatemala, a community based organization; all other authors declare no competing interests.

#### **Data sharing statement**

Data from the reference datasets can be found in the public domain: NHANES at <https://www.cdc.gov/nchs/nhanes/index.htm> and Health Survey England at <https://beta.ukdataservice.ac.uk/datacatalogue/series/series?id=2000021>.

Data for the other included studies may be available by contacting the authors of the respective study papers.

#### **Acknowledgements**

We thank all the participating studies, their researchers, and fieldworkers, along with all the participants for enabling this work to be completed.

## Author contributions

N.P. and B.C. conceived and designed the study; N.P., B.C., K.J., J.G., D.N., V.J., A.S., and R.C-R. wrote the study protocol; P.C., P.D., V.J., P.K., S.M., R.R.T., A.B., P.R., M.H.H., A.C., M.D., A.P., A.B-O., C.O'C-G., P.C., N.G., T.R., S.C.W., S.S, C.K., M.G-Q., S.C., A.A. and D.N. collected and contributed data; C.E.R and S.R. were responsible for data cleaning and management; C.E.R. and M.N. analysed and visualised the data; C.E.R, N.P. and B.C. wrote the first draft of the manuscript; all other authors contributed to revisions of the manuscript. Others also contributed to the planning and conduct of the study, and to the revisions of the paper, and are listed below as part of the DEGREE Study Group.

Supplementary material is available online at [www.kidney-international.org](http://www.kidney-international.org).

## References

1. Johnson RJ, Wesseling C, Newman LS. Chronic Kidney Disease of Unknown Cause in Agricultural Communities. *N Engl J Med*. 2019 May 9;380(19):1843-1852. doi: 10.1056/NEJMra1813869
2. Jayasumana C, Orantes C, Herrera R, *et al*. Chronic interstitial nephritis in agricultural communities: a worldwide epidemic with social, occupational and environmental determinants. *Nephrol Dial Transplant*. 2017 Feb 1;32(2):234-241. doi: 10.1093/ndt/gfw346
3. Torres C, Aragón A, González M, *et al*. Decreased kidney function of unknown cause in Nicaragua: a community-based survey. *Am J Kidney Dis*. 2010 Mar;55(3):485-96. doi: 10.1053/j.ajkd.2009.12.012. Epub 2010 Feb 8
4. Aguilar-Ramirez D, Raña-Custodio A, Villa A, *et al*. Decreased kidney function and agricultural work: a cross-sectional study in middle-aged adults from Tierra Blanca, Mexico. *Nephrol Dial Transplant*. 2021 May 27;36(6):1030-1038. doi: 10.1093/ndt/gfaa041
5. O'Callaghan-Gordo C, Shivashankar R, Anand S, *et al*. Prevalence of and risk factors for chronic kidney disease of unknown aetiology in India: secondary data analysis of three population-based cross-sectional studies. *BMJ Open*. 2019 Mar 7;9(3):e023353. doi: 10.1136/bmjopen-2018-023353. Erratum in: *BMJ Open*. 2019 Mar 18;9(3):e023353corr1
6. Ruwanpathirana T, Senanayake S, Gunawardana N, *et al*. Prevalence and risk factors for impaired kidney function in the district of Anuradhapura, Sri Lanka: a cross-sectional population-representative survey in those at risk of chronic kidney disease of unknown aetiology. *BMC Public Health*. 2019 Jun 14;19(1):763. doi: 10.1186/s12889-019-7117-2
7. Pearce N, Caplin B. Let's take the heat out of the CKDu debate: more evidence is needed. *Occup Environ Med*. 2019 Jun;76(6):357-359. doi: 10.1136/oemed-2018-105427. Epub 2019 Mar 30

8. Keogh SA, Leibler JH, Sennett Decker CM, *et al.* High prevalence of chronic kidney disease of unknown etiology among workers in the Mesoamerican Nephropathy Occupational Study. *BMC Nephrol.* 2022 Jul 7;23(1):238. doi: 10.1186/s12882-022-02861-0
9. Jelaković B, Dika Ž, Arlt VM, *et al.* Balkan Endemic Nephropathy and the Causative Role of Aristolochic Acid. *Semin Nephrol.* 2019 May;39(3):284-296. doi: 10.1016/j.semnephrol.2019.02.007
10. González-Quiroz M, Pearce N, Caplin B, *et al.* What do epidemiological studies tell us about chronic kidney disease of undetermined cause in Meso-America? A systematic review and meta-analysis. *Clin Kidney J.* 2018 Aug;11(4):496-506. doi: 10.1093/ckj/sfx136. Epub 2017 Dec 8
11. Wesseling C, Glaser J, Rodríguez-Guzmán J, *et al.* Chronic kidney disease of non-traditional origin in Mesoamerica: a disease primarily driven by occupational heat stress. *Rev Panam Salud Publica.* 2020 Jan 27;44:e15. doi: 10.26633/RPSP.2020.15
12. Redmon JH, Levine KE, Lebov J, *et al.* A comparative review: Chronic Kidney Disease of unknown etiology (CKDu) research conducted in Latin America versus Asia. *Environ Res.* 2021 Jan;192:110270. doi: 10.1016/j.envres.2020.110270. Epub 2020 Oct 7. PMID: 33035557
13. Pearce N. Global epidemiology: the importance of international comparisons and collaborations. *Open Access Epidemiology* 2013; 1: 15
14. Pearce N. Traditional epidemiology, modern epidemiology, and public health. *Am J Public Health.* 1996 May;86(5):678-83. doi: 10.2105/ajph.86.5.678
15. The International Study of Asthma and Allergies in Childhood (ISAAC) Steering Committee. Worldwide variations in the prevalence of asthma symptoms: the International Study of Asthma and Allergies in Childhood (ISAAC). *Eur Respir J* 1998; 12(2): 315-335
16. Lai CKW, Beasley R, Crane J, *et al.* Global variation in the prevalence and severity of asthma symptoms: phase three of the International Study of Asthma and Allergies in Childhood (ISAAC). *Thorax.* 2009;64(6):476-483. doi: 10.1136/thx.2008.106609. Epub 2009 Feb 22
17. García-Marcos L, Asher MI, Pearce N, *et al.* The burden of asthma, hay fever and eczema in children in 25 countries: GAN Phase I study. *Eur Respir J.* 2022 Sep 15;60(3):2102866. doi: 10.1183/13993003.02866-2021.
18. Mortimer K, Lesosky M, García-Marcos L, *et al.* The burden of asthma, hay fever and eczema in adults in 17 countries: GAN Phase I study. *Eur Respir J.* 2022 Sep 15;60(3):2102865. doi: 10.1183/13993003.02865-2021
19. Caplin B, Jakobsson K, Glaser J, *et al.* International Collaboration for the Epidemiology of eGFR in Low and Middle Income Populations – Rationale and core protocol for the Disadvantaged Populations eGFR Epidemiology Study (DEGREE). *BMC Nephrol* 18, 1 (2017). doi: 10.1186/s12882-016-0417-1
20. Ferreccio C, Roa JC, Bambs C, *et al.* Study protocol for the Maule Cohort (MAUCO) of chronic diseases, Chile 2014-2024. *BMC Public Health.* 2016 Feb 4;16:122. doi: 10.1186/s12889-015-2454-2

21. Gualan M, Ster IC, Veloz T, *et al.* Cardiometabolic diseases and associated risk factors in transitional rural communities in tropical coastal Ecuador. *PLoS One.* 2024 Jul 18;19(7):e0307403. doi: 10.1371/journal.pone.0307403
22. NatCen Social Research, University College London, Department of Epidemiology and Public Health. (2023). Health Survey for England, 2016. [data collection]. *4th Edition.* UK Data Service. SN: 8334, doi: 10.5255/UKDA-SN-8334-4
23. Miller AC, Tuiz E, Shaw L, *et al.* Population Estimates of GFR and Risk Factors for CKD in Guatemala. *Kidney Int Rep.* 2021 Jan 1;6(3):796-805. doi: 10.1016/j.ekir.2020.12.015
24. Nair M, Ali MK, Ajay VS, *et al.* CARRS Surveillance study: design and methods to assess burdens from multiple perspectives. *BMC Public Health* 12, 701 (2012). doi: 10.1186/1471-2458-12-701
25. Prabhakaran D, Roy A, Praveen PA, *et al.* 20-Year Trend of CVD Risk Factors: Urban and Rural National Capital Region of India. *Glob Heart.* 2017 Sep;12(3):209-217. doi: 10.1016/j.gheart.2016.11.004. Epub 2017 Apr 11
26. Mohan S, Jarhyan P, Ghosh S, *et al.* UDAY: A comprehensive diabetes and hypertension prevention and management program in India. *BMJ Open.* 2018 Jul 10;8(6):e015919. doi: 10.1136/bmjopen-2017-015919
27. Gummidi B, John O, Ghosh A, *et al.* A Systematic Study of the Prevalence and Risk Factors of CKD in Uddanam, India. *Kidney Int Rep.* 2020 Oct 16;5(12):2246-2255. doi: 10.1016/j.ekir.2020.10.004
28. De Marchi B, Ficorilli A and Biggeri A. (2022). Research is in the air in Valle del Serchio. *Futures.* 137. 10.1016/j.futures.2022.102906
29. Hathaway MH, Patil CL, Odhiambo A, *et al.* Prevalence and predictors of chronic kidney disease of undetermined causes (CKDu) in Western Kenya's "sugar belt": a cross-sectional study. *BMC Nephrol.* 2023 Jun 6;24(1):157. doi: 10.1186/s12882-023-03213-2
30. Hamilton SA, Nakanga WP, Prynn JE, *et al.* Prevalence and risk factors for chronic kidney disease of unknown cause in Malawi: a cross-sectional analysis in a rural and urban population. *BMC Nephrol.* 2020 Sep 7;21(1):387. doi: 10.1186/s12882-020-02034-x
31. Poudyal A, Karki KB, Shrestha N, *et al.* Prevalence and risk factors associated with chronic kidney disease in Nepal: evidence from a nationally representative population-based cross-sectional study. *BMJ Open.* 2022 Mar 21;12(3):e057509. doi: 10.1136/bmjopen-2021-057509
32. Strasma A, Reyes ÁM, Aragón A, *et al.* Kidney disease characteristics, prevalence, and risk factors in León, Nicaragua: a population-based study. *BMC Nephrol.* 2023 Nov 12;24(1):335. doi: 10.1186/s12882-023-03381-1
33. Ruiz-Alejos A, Caplin B, Miranda JJ, *et al.* CKD and CKDu in northern Peru: a cross-sectional analysis under the DEGREE protocol. *BMC Nephrol.* 2021 Jan 21;22(1):37. doi: 10.1186/s12882-021-02239-8
34. Aekplakorn W, Chariyalertsak S, Kessomboon P, *et al.* Women and other risk factors for chronic kidney disease of unknown etiology in Thailand: National Health Examination V Survey. *Sci Rep.* 2021 Nov 1;11(1):21366. doi: 10.1038/s41598-021-00694-9. Erratum in: *Sci Rep.* 2021 Nov 16;11(1):22674



35. Centers for Disease Control and Prevention (CDC). National Center for Health Statistics (NCHS). National Health and Nutrition Examination Survey 2017-2018 Data. Hyattsville, MD: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, <https://www.cdc.gov/nchs/nhanes/index.htm>. Accessed 03/10/2023
36. Pottel H, Cavalier E, Björk J, *et al.* Standardization of serum creatinine is essential for accurate use of unbiased estimated GFR equations: evidence from three cohorts matched on renal function. *Clin Kidney J.* 2022 Aug 3;15(12):2258-2265. doi: 10.1093/ckj/sfac182
37. Ahmad O, Boschi-Pinto C, Lopez A, *et al.* Age standardization of rates: a new WHO standard. GPE Discussion Paper Series, No.31. Geneva: World Health Organization; 2001, <http://www.who.int/healthinfo/paper31.pdf>. Accessed 01/08/2023
38. Levey AS, Stevens LA, Schmid CH, *et al.*; for the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) . A New Equation to Estimate Glomerular Filtration Rate. *Ann Intern Med.* 2009;150:604-612. [Epub 5 May 2009]. doi:10.7326/0003-4819-150-9-200905050-00006
39. Inker LA, Schmid CH, Tighiouart H, *et al.* Estimating glomerular filtration rate from serum creatinine and cystatin C. *N Engl J Med.* 2012 Jul 5;367(1):20-9. doi: 10.1056/NEJMoa1114248. Erratum in: *N Engl J Med.* 2012 Aug 16;367(7):681. Erratum in: *N Engl J Med.* 2012 Nov 22;367(21):2060.
40. Jonsson AJ, Lund SH, Eriksen BO, *et al.* The prevalence of chronic kidney disease in Iceland according to KDIGO criteria and age-adapted estimated glomerular filtration rate thresholds. *Kidney Int.* 2020 Nov;98(5):1286-1295. doi: 10.1016/j.kint.2020.06.017. Epub 2020 Jul 3. PMID: 32622831.
41. StataCorp. 2021. *Stata Statistical Software: Release 17*. College Station, TX: StataCorp LLC
42. QGIS.org. QGIS Geographic Information System. QGIS Association. [www.qgis.org](http://www.qgis.org)
43. Orantes-Navarro CM, Almaguer-López MM, Alonso-Galbán P, *et al.* The Chronic Kidney Disease Epidemic in El Salvador: A Cross-Sectional Study. *MEDICC Rev.* 2019 Apr-Jul;21(2-3):29-37. doi: 10.37757/MR2019.V21.N2-3.7
44. Cha'on U, Tippayawat P, Sae-Ung N, *et al.* High prevalence of chronic kidney disease and its related risk factors in rural areas of Northeast Thailand. *Sci Rep.* 2022 Oct 28;12(1):18188. doi: 10.1038/s41598-022-22538-w
45. Dhakal N, Singh DS. SAT-136 chronic kidney disease in migrant workers in Nepal. *Kidney International Reports.* 2020;5(3):S58. <https://doi.org/10.1016/j.ekir.2020.02>
46. Kumar V, Yadav AK, Yasuda Y, *et al.* Existing creatinine-based equations overestimate glomerular filtration rate in Indians. *BMC Nephrol* 19, 22 (2018). doi: 10.1186/s12882-018-0813-9
47. Fabian J, Kalyesubula R, Mkandawire J, *et al.* African Research on Kidney Disease Consortium. Measurement of kidney function in Malawi, South Africa, and Uganda: a multicentre cohort study. *Lancet Glob Health.* 2022 Aug;10(8):e1159-e1169. doi: 10.1016/S2214-109X(22)00239-X
48. Wang Y, Levey AS, Inker LA, *et al.* Performance and Determinants of Serum Creatinine and Cystatin C-Based GFR Estimating Equations in South Asians. *Kidney Int Rep.* 2021 Jan 16;6(4):962-975. doi: 10.1016/j.ekir.2021.01.005

49. Gallo-Ruiz L, Sennett CM, Sánchez-Delgado M, *et al.* Prevalence and Risk Factors for CKD Among Brickmaking Workers in La Paz Centro, Nicaragua. *Am J Kidney Dis.* 2019 Aug;74(2):239-247. doi: 10.1053/j.ajkd.2019.01.017. Epub 2019 Feb 27
50. Venugopal V, Lennqvist R, Latha PK, *et al.* Occupational Heat Stress and Kidney Health in Salt Pan Workers. *Kidney Int Rep.* 2023 Apr 20;8(7):1363-1372. doi: 10.1016/j.ekir.2023.04.011

### Figure Legends

**Figure 1:** Age-standardised prevalence of creatinine-based eGFR<60 in rural<sup>a</sup> men without hypertension, diabetes, or heavy proteinuria

<sup>a</sup>USA includes rural and urban together; eGFR=estimated glomerular filtration rate in ml/min/1.73m<sup>2</sup>

**Figure 2:** Age-standardised prevalence of creatinine-based eGFR<60 in urban<sup>a</sup> men without hypertension, diabetes, or heavy proteinuria

<sup>a</sup>USA includes rural and urban together; eGFR=estimated glomerular filtration rate in ml/min/1.73m<sup>2</sup>

**Figure 3:** Age-standardised prevalence of creatinine-based eGFR<60 in rural<sup>a</sup> women without hypertension, diabetes, or heavy proteinuria

<sup>a</sup>USA includes rural and urban together; eGFR=estimated glomerular filtration rate in ml/min/1.73m<sup>2</sup>

**Figure 4:** Age-standardised prevalence of creatinine-based eGFR<60 in urban<sup>a</sup> women without hypertension, diabetes, or heavy proteinuria

<sup>a</sup>USA includes rural and urban together; eGFR=estimated glomerular filtration rate in ml/min/1.73m<sup>2</sup>

**Figure 5:** Age-standardised prevalence of eGFR<60 by sex in population without hypertension, diabetes mellitus, or heavy proteinuria

eGFR=estimated glomerular filtration rate in ml/min/1.73m<sup>2</sup>

Table 1: Characteristics of study areas and samples

Country	Study type	Rationale	Area name	Urban % <sup>a</sup>	Climate	Survey dates	Survey season	Source Population	Overall response rate %	Sample information <sup>b</sup>		
										n	male %	age, years median (IQR)
Chile	Reuse of population survey <sup>20</sup>	Proposed risk factors	Molina	69	Mediterranean	Oct22-Nov23	All year	45 976	92	476	41	53 (48, 57)
Ecuador	CKD focused study <sup>21</sup>	DEGREE registered	Miguelillo, Manabi Province	0	Tropical	Jul21-Sep21	Dry	14 164	61	754	41	39 (28, 49)
England	HSE 2016 – Reuse of population survey <sup>22</sup>	Reference	England	83	Temperate	2016	All year	56 000 000	59	2 135	42	44 (34, 52)
Guatemala	CKD focused study <sup>23</sup>	DEGREE registered	Tecpán, Chimaltenango	0	Temperate Highland Tropical	Jun18-Oct19	All year	85 000	58	336	34	34 (24, 47)
			San Antonio Suchitepéquez	0	Tropical Wet	Jun18-Oct19	All year	52 000	69	318	34	33 (25, 45)
India	1. CARRS - Reuse of population survey <sup>24</sup>	DEGREE registered	Chennai	100	Tropical	Oct10-Nov11	All year	4 680 000	92	5 366	43	39 (31, 47)
			Delhi	100	Semi-arid	Oct10-Nov11	All year	16 300 000	96	3 564	49	42 (35, 50)
	2. ICMR-CHD – Reuse of population survey <sup>25</sup>	DEGREE registered	Delhi	100	Semi-arid	Aug11-Jan12	Rainy, autumn, winter	16 300 000	Not reported	1 888	44	41 (35, 48)
			Faridabad	0	Semi-arid	Aug11-Jan12	Rainy, autumn, winter	90 000	Not reported	1 413	45	42 (36, 49)
	3. UDAY - Reuse of population survey <sup>26</sup>	DEGREE registered	Sonipat	50	Semi-arid	Jul14-Dec14	Rainy, autumn, winter	203 000	90 <sup>c</sup>	4 126	44	44 (37, 51)
			Vizag	50	Tropical	Jul14-Dec14	Rainy, autumn, winter	275 000		4 209	44	43 (35, 50)
	4. Uddanam - CKD focused study <sup>27</sup>	Reported high CKDu area	Kanchili	0	Hot Tropical	Jun18- Dec19	Summer, winter	66 657	85 <sup>c</sup>	317	47	43 (35, 51)
			Kaviti	0	Hot Tropical	Jun18-Dec19	Summer, winter	75 974		212	48	43 (35, 51)
			Mandasa	0	Hot Tropical	Jun18-Dec19	Summer, winter	82 699		200	48	42 (33, 50)
			Palasa	0	Hot Tropical	Jun18-Dec19	Summer, winter	97 551		362	51	44 (36, 51)
			Sompeta	0	Hot Tropical	Jun18-Dec19	Summer, winter	78 908		443	46	42 (33, 51)
V_kothuru	0	Hot Tropical	Jun18-Dec19	Summer, winter	73 212	531	47	44 (35, 52)				
5. Prakasam – CKD focused study <sup>d</sup>	DEGREE registered	Kanigiri	0	Hot Tropical	Dec21-Feb22	Winter	1 780	84	1 052	40	39 (30, 49)	
Italy	CKD focused study <sup>28</sup>	Reported high CKD area	Barga	0	Temperate	Jun21-Mar22	Summer, autumn, winter	9 574	92 <sup>e</sup> (or 50 <sup>f</sup> )	301	43	47 (33, 54)
Kenya	CKD focused study <sup>29</sup>	DEGREE registered	Muhoroni East	100	Sub-tropical	Jul20-Nov20	Dry	3 740	85	260	53	34 (26, 43)
			Owaga	0	Sub-tropical	Jul20-Nov20	Dry	3 769	87	242	47	36 (26, 46)
			Tonde	0	Sub-tropical	Jul20-Nov20	Dry	3 045	98	233	49	36 (28, 45)
Malawi	CKD focused study <sup>30</sup>	DEGREE registered	Southern Karonga District	0	Sub-tropical	Jan18-Aug18	Dry, rainy	40 000	66	646	42	33 (24, 41)
			Lilongwe	100	Sub-tropical	Jan18-Aug18	Dry, rainy	66 000	37	312	31	28 (22, 38)

<b>Nepal</b>	Reuse of population survey <sup>31</sup>	Proposed risk factors	Nepal	67	Sub-tropical to Arctic	2016-2018	All year	29 000 000	92	8 916	37	41 (33, 50)
<b>Nicaragua</b>	1. CKD focused study <sup>3</sup>	Reported high CKDu area	Chinandega (banana/sugarcane)	0	Tropical	Jul07-Oct07	Rainy	384	86	331	47	34 (26, 44)
			Chinandega (service)	0	Tropical	Jul07-Oct07	Rainy	177	79	140	36	32 (25, 43)
			Leon (coffee)	0	Tropical	Jul07-Oct07	Rainy	92	84	77	52	36 (27, 46)
			Leon (fishing)	0	Tropical	Jul07-Oct07	Rainy	216	77	166	46	32 (25, 44)
			Leon (mining)	0	Tropical	Jul07-Oct07	Rainy	445	86	382	41	33 (26, 43)
2. CKD focused study <sup>32</sup>	Reported high CKDu area	Leon municipality	70	Tropical	Jun14-Sep14	Rainy	204 000	97	1 672	39	37 (28, 48)	
<b>Peru</b>	CKD focused study <sup>33</sup>	DEGREE registered	Tumbes	94	Arid and Sub-tropical	Nov17-May18	Spring, summer, autumn	224 863	83	1 238	43	39 (30, 49)
<b>Sri Lanka</b>	Anuradhapura District - CKD focused study <sup>6</sup>	DEGREE registered	Halambagaswewa, Rambewa	0	Tropical	Mar17-May17	Dry	1 188	90	739	33	41 (33, 49)
			Lolugaswewa, Medawachchiya	0	Tropical	Mar17-May17	Dry	1 262	86	790	28	41 (34, 50)
			Pothana, Mihintale	0	Tropical	Mar17-May17	Dry	1 391	88	691	28	41 (33, 51)
			Puhudivula, Medawachchiya	0	Tropical	Mar17-May17	Dry	1 362	91	798	28	41 (32, 50)
			Sangilikandarawa, Rambewa	0	Tropical	Mar17-May17	Dry	1 228	90	818	33	41 (33, 50)
<b>Thailand</b>	Reuse of population survey <sup>34</sup>	Proposed risk factors	Bangkok	100	Tropical	Nov13-Aug14	Cool, hot, rainy	6 969 010 <sup>g</sup>	81	1 604	24	48 (40, 55)
			Central	46	Tropical	Nov13-Aug14	Cool, hot, rainy	14 424 785 <sup>g</sup>	92	2 752	41	46 (35, 54)
			North	35	Tropical	Nov13-Aug14	Cool, hot, rainy	8 638 732 <sup>g</sup>	83	2 447	45	47 (37, 54)
			North East	29	Tropical	Nov13-Aug14	Cool, hot, rainy	13 445 305 <sup>g</sup>	80	2 315	46	46 (36, 53)
			South	34	Tropical	Nov13-Aug14	Cool, hot, rainy	6 442 937 <sup>g</sup>	73	2 019	42	44 (34, 53)
<b>USA</b>	NHANES 2017-8 – Reuse of population survey <sup>35</sup>	Reference	USA	83	All types	2017-2018	All year	320 842 721	49	3373	47	39 (30, 49)

<sup>a</sup> Proportion of the source population of the area living in an urban environment <sup>b</sup> includes ages 18-60 with complete data available; <sup>c</sup> overall response rate not area-specific; <sup>d</sup> personal communication Professor Prabhdeep Kaur (kprabhdeep@gmail.com); <sup>e</sup> denominator includes refusal/incomplete surveys but excludes mailing failures; <sup>f</sup> denominator includes mailing failures; <sup>g</sup> population over age 20; HSE=Health Survey England; CARRS=Centre for cArdiometabolic Risk Reduction in South-Asia; ICMR-IHD=Indian Council of Medical Research International Health Division; UDAY=means dawn in Sanskrit; NHANES=National Health and Nutrition Examination Survey;

Table 2: Age-standardised prevalence of eGFR<60 ml/min per 1.73m<sup>2</sup> by sex, for ages 18-60

Centre	Area	Rural / Urban	Sample with complete data				Sample of people without hypertension, diabetes, or heavy proteinuria			
			Men		Women		Men		Women	
			n	eGFR<60 <sup>a</sup> % (95% CI)	n	eGFR<60 <sup>a</sup> % (95% CI)	n	eGFR<60 <sup>a</sup> % (95% CI)	n	eGFR<60 <sup>a</sup> % (95% CI)
Chile <sup>b</sup>	Molina	Rural	39	0.0 (N/A)	17	0.0 (N/A)	16	0.0 (N/A)	6	0.0 (N/A)
Chile <sup>b</sup>	Molina	Urban	156	0.0 (N/A)	264	1.6 (0.1, 3.1)	66	0.0 (N/A)	137	0.5 (0, 1.6)
Ecuador	Miguelillo	Rural	312	2.2 (0.7, 3.8)	442	6.4 (4.3, 8.5)	180	1.2 (0, 2.8)	235	6.0 (2.2, 9.7)
England	all	Rural	161	0.4 (0, 1.0)	223	2.2 (0.8, 3.7)	98	0.0 (N/A)	169	1.8 (0.4, 3.2)
England	all	Urban	744	0.5 (0.1, 0.9)	1007	1.0 (0.6, 1.5)	515	0.1 (0, 0.4)	759	0.8 (0.3, 1.4)
Guatemala	San Antonio Suchitepequez	Rural	115	3.1 (0, 6.3)	221	0.9 (0, 2.2)	86	3.0 (0, 7.0)	171	0.0 (N/A)
Guatemala	Tecpan	Rural	109	0.9 (0, 2.6)	209	0.0 (N/A)	83	0.0 (N/A)	152	0.0 (N/A)
India 1 (CARRS)	Chennai	Urban	2333	0.9 (0.5, 1.3)	3033	0.6 (0.3, 0.9)	1161	0.5 (0.0, 0.9)	1915	0.2 (0, 0.5)
India 1 (CARRS)	Delhi	Urban	1733	1.0 (0.6, 1.5)	1831	1.2 (0.8, 1.6)	770	0.6 (0.1, 1.1)	935	0.6 (0.0, 1.1)
India 2 (ICMR)	Delhi	Urban	837	1.2 (0.6, 1.9)	1051	2.3 (1.5, 3.1)	399	0.6 (0, 1.3)	571	1.8 (0.6, 3.0)
India 2 (ICMR)	Faridabad	Rural	629	1.6 (0.8, 2.4)	784	1.6 (0.9, 2.4)	380	1.9 (0.8, 3.1)	520	1.5 (0.5, 2.5)
India 3 (UDAY)	Sonipat	Rural	768	0.6 (0.2, 1.1)	1136	0.6 (0.2, 1.0)	530	0.4 (0.0, 0.8)	847	0.5 (0.1, 0.9)
India 3 (UDAY)	Sonipat	Urban	1038	0.9 (0.4, 1.3)	1184	0.6 (0.2, 0.9)	586	0.6 (0.1, 1.1)	768	0.3 (0, 0.6)
India 3 (UDAY)	Vizag	Rural	934	6.7 (2.9, 10.4)	1242	3.1 (2.2, 4.1)	696	6.5 (1.9, 11.0)	933	2.6 (1.5, 3.7)
India 3 (UDAY)	Vizag	Urban	903	1.2 (0.6, 1.8)	1130	0.7 (0.3, 1.1)	469	0.4 (0, 1.1)	692	0.5 (0, 1.1)
India 4 (Uddanam)	Kanchili	Rural	148	4.8 (1.1, 8.6)	169	7.2 (3.2, 11.3)	71	6.9 (1.0, 12.9)	83	1.1 (0, 3.2)
India 4 (Uddanam)	Kaviti	Rural	102	12.2 (7.7, 16.7)	110	8.0 (3.5, 12.4)	52	6.7 (1.3, 12.2)	65	8.0 (2.0, 14.1)
India 4 (Uddanam)	Mandasa	Rural	95	18.4 (10.7, 26.1)	105	10.6 (6.0, 15.1)	57	13.7 (4.8, 22.6)	54	5.6 (0.4, 10.7)
India 4 (Uddanam)	Palasa	Rural	186	11.2 (5.9, 16.5)	176	11.0 (6.1, 15.9)	84	6.8 (0.1, 13.4)	81	4.6 (0.5, 8.7)
India 4 (Uddanam)	Sompeta	Rural	202	9.2 (4.9, 13.4)	241	2.7 (0.9, 4.5)	99	8.2 (2.2, 14.3)	127	5.8 (1.1, 10.6)
India 4 (Uddanam)	V_kothuru	Rural	250	5.3 (3.0, 7.5)	281	4.9 (2.9, 7.0)	101	2.1 (0, 4.8)	121	7.5 (3.2, 11.9)
India 5 (Prakasam)	Kanigiri	Rural	420	5.3 (3.4, 7.2)	632	3.4 (2.0, 4.7)	221	2.5 (0.3, 4.6)	432	1.9 (0.7, 3.1)
Italy	Barga	Rural	128	0.9 (0, 2.3)	173	0.7 (0, 1.7)	73	1.2 (0, 3.5)	149	0.0 (N/A)
Kenya	Muhoroni East	Urban	138	0.0 (N/A)	122	0.9 (0, 2.7)	113	0.0 (N/A)	104	0.0 (N/A)
Kenya	Owaga	Rural	113	0.0 (N/A)	129	2.2 (0, 4.8)	88	0.0 (N/A)	98	2.4 (0, 5.8)
Kenya	Tonde	Rural	114	0.0 (N/A)	119	0.0 (N/A)	94	0.0 (N/A)	100	0.0 (N/A)
Malawi	Karonga	Rural	271	3.0 (0.7, 5.4)	375	3.0 (1.0, 5.1)	214	1.4 (0, 3.5)	309	2.8 (0.3, 5.3)
Malawi	Lilongwe	Urban	96	2.2 (0, 6.2)	216	4.9 (1.4, 8.4)	74	3.1 (0, 8.6)	159	4.0 (0.7, 7.2)
Nepal	all	Rural	1690	0.9 (0.6, 1.3)	2790	2.1 (1.6, 2.6)	1002	0.5 (0.1, 1.0)	1981	1.7 (1.1, 2.3)
Nepal	all	Urban	1602	0.8 (0.4, 1.1)	2834	3.0 (2.4, 3.6)	822	0.3 (0.0, 0.7)	1777	2.6 (1.9, 3.4)
Nicaragua 1	Chinandega (banana/sugarcane)	Rural	155	19.0 (12.5, 25.5)	176	3.5 (0.6, 6.4)	104	13.6 (6.3, 20.9)	111	0.0 (N/A)

Nicaragua 1	Chinandega (service)	Rural	50	0.0 (N/A)	90	0.0 (N/A)	34	0.0 (N/A)	58	0.0 (N/A)
Nicaragua 1	Leon (coffee)	Rural	40	6.3 (0, 14.4)	37	0.0 (N/A)	30	8.6 (0, 19.1)	26	0.0 (N/A)
Nicaragua 1	Leon (fishing)	Rural	76	10.2 (3.2, 17.3)	90	2.1 (0, 5.9)	55	6.4 (0, 13.0)	73	0.0 (N/A)
Nicaragua 1	Leon (mining/subsistence farming)	Rural	158	16.2 (10.4, 22.0)	224	4.8 (1.7, 7.9)	106	12.1 (4.5, 19.6)	144	2.6 (0, 6.6)
Nicaragua 2	Leon municipalities	Rural	247	15.3 (10.9, 19.7)	329	3.1 (1.2, 5.0)	145	9.4 (4.4, 14.3)	211	2.5 (0, 5.4)
Nicaragua 2	Leon municipalities	Urban	400	10.0 (7.2, 12.7)	696	3.6 (2.3, 4.8)	256	6.6 (3.0, 10.1)	436	2.4 (1.0, 3.9)
Peru	Tumbes	Rural	278	0.5 (0, 1.3)	344	0.3 (0, 0.9)	210	0.0 (N/A)	285	0.6 (0, 1.7)
Peru	Tumbes	Urban	257	0.5 (0, 1.2)	359	0.5 (0, 1.1)	186	0.0 (N/A)	305	0.0 (N/A)
Sri Lanka	Halambagaswewa	Rural	242	8.3 (5.5, 11.0)	497	3.8 (2.2, 5.3)	136	3.9 (1.1, 6.8)	336	1.3 (0.1, 2.6)
Sri Lanka	Lolugaswewa	Rural	221	5.8 (3.5, 8.1)	569	4.5 (3.1, 5.9)	138	7.7 (3.9, 11.5)	372	2.6 (1.0, 4.2)
Sri Lanka	Pothana	Rural	194	5.0 (2.6, 7.3)	497	1.7 (0.7, 2.6)	115	0.7 (0, 1.9)	330	0.7 (0, 1.6)
Sri Lanka	Puhudivula	Rural	222	7.7 (5.2, 10.2)	576	3.6 (2.3, 5.0)	112	7.6 (3.8, 11.3)	378	1.4 (0.2, 2.6)
Sri Lanka	Sangilikandarawa	Rural	270	6.1 (3.8, 8.4)	548	2.9 (1.6, 4.3)	157	3.1 (0.6, 5.6)	346	2.4 (0.8, 3.9)
Thailand	Bangkok	Urban	381	1.1 (0.1, 2.2)	1223	0.7 (0.0, 1.3)	233	1.2 (0, 2.7)	943	0.5 (0, 1.1)
Thailand	Central	Rural	606	0.9 (0.3, 1.4)	795	1.1 (0.4, 1.9)	424	0.2 (0, 0.4)	576	1.0 (0.1, 1.8)
Thailand	Central	Urban	519	0.6 (0.1, 1.1)	832	0.4 (0.1, 0.7)	336	0.0 (N/A)	587	0.2 (0, 0.5)
Thailand	North	Rural	668	1.1 (0.6, 1.7)	730	1.0 (0.1, 1.8)	407	0.4 (0, 0.9)	498	0.5 (0, 1.3)
Thailand	North	Urban	445	1.1 (0, 2.3)	604	1.0 (0.4, 1.6)	267	0.7 (0, 1.9)	409	0.3 (0, 0.7)
Thailand	North East	Rural	577	1.3 (0.5, 2.1)	637	0.8 (0.3, 1.3)	428	0.6 (0.1, 1.2)	479	0.3 (0, 0.7)
Thailand	North East	Urban	492	0.7 (0, 1.4)	609	0.6 (0.2, 1.0)	351	0.2 (0, 0.5)	450	0.1 (0, 0.4)
Thailand	South	Rural	549	0.5 (0.1, 1.0)	678	0.2 (0, 0.5)	366	0.2 (0, 0.6)	493	0.2 (0, 0.5)
Thailand	South	Urban	303	0.7 (0.0, 1.4)	489	1.1 (0.3, 2.0)	193	1.1 (0, 2.4)	356	0.7 (0, 1.4)
USA	all	All	1586	2.1 (1.4, 2.8)	1787	1.3 (0.8, 1.8)	925	0.6 (0.1, 1.0)	1143	0.7 (0.2, 1.2)

<sup>a</sup> age-standardised prevalence using WHO global population age weights; <sup>b</sup> only 41-60 years included; eGFR=creatinine-based estimated glomerular filtration rate; CI=confidence interval using normal approximation; N/A=no CI available due to zero estimate

Table 3: Age-standardised<sup>a</sup> prevalence rates of creatinine- and cystatin C-based eGFR<60 ml/min per 1.73m<sup>2</sup> in people without hypertension, diabetes, or heavy proteinuria, by sex, for ages 18-60 years with both creatinine and cystatin C measurements available

Centre	Area	Rural / Urban	Men			Women				
			n	CKD-EPI 2009 <sub>creat</sub> % (95% CI)	CHKD-EPI 2012 <sub>cys</sub> % (95% CI)	CKD-EPI 2012 <sub>creat-cys</sub> % (95% CI)	n	CKD-EPI 2009 <sub>creat</sub> % (95% CI)	CHKD-EPI 2012 <sub>cys</sub> % (95% CI)	CKD-EPI 2012 <sub>creat-cys</sub> % (95% CI)
England	all	Rural	98	0.0 (N/A) <sup>b</sup>	0.5 (0, 1.4)	- <sup>c</sup>	169	1.8 (0.4, 3.2) <sup>b</sup>	0.3 (0, 0.8)	- <sup>c</sup>
England	all	Urban	515	0.1 (0, 0.4) <sup>b</sup>	0.8 (0.1, 1.4)	- <sup>c</sup>	759	0.8 (0.3, 1.4) <sup>b</sup>	0.4 (0, 0.7)	- <sup>c</sup>
India 3 (UDAY)	Sonipat	Rural	177	0.3 (0, 0.9)	14.3 (10.5, 18.0)	1.7 (0.2, 3.2)	253	0.0 (N/A)	12.9 (7.3, 18.4)	0.6 (0, 1.3)
India 3 (UDAY)	Sonipat	Urban	199	0.0 (N/A)	14.1 (10.4, 17.8)	2.5 (0.7, 4.3)	273	0.0 (N/A)	14.1 (10.6, 17.6)	2.8 (0.8, 4.8)
India 3 (UDAY)	Vizag	Rural	269	6.7 (0, 15.2)	21.3 (9.9, 32.6)	10.1 (1.5, 18.8)	325	2.8 (1.2, 4.5)	12.1 (8.7, 15.5)	4.8 (2.7, 7.0)
India 3 (UDAY)	Vizag	Urban	152	0.0 (N/A)	12.5 (3.2, 21.9)	0.4 (0, 1.2)	244	0.0 (N/A)	12.8 (8.1, 17.5)	2.1 (0.1, 4.1)
Kenya	Muhoroni East	Urban	4	0.0 (N/A)	0.0 (N/A)	0.0 (N/A)	9	0.0 (N/A)	0.0 (N/A)	0.0 (N/A)
Kenya	Owaga	Rural	37	0.0 (N/A)	3.6 (0, 10.0)	0.0 (N/A)	43	0.0 (N/A)	10.4 (4.8, 16.0)	0.0 (N/A)
Kenya	Tonde	Rural	19	0.0 (N/A)	0.0 (N/A)	0.0 (N/A)	29	0.0 (N/A)	14.3 (3.7, 24.9)	0.0 (N/A)
Malawi	Karonga	Rural	214	1.4 (0, 3.5)	1.1 (0, 2.6)	1.8 (0, 4.0)	309	2.8 (0.3, 5.3)	1.6 (0, 3.8)	2.3 (0, 4.7)
Malawi	Lilongwe	Urban	74	3.1 (0, 8.6)	0.7 (0, 2.1)	0.0 (N/A)	159	4.0 (0.7, 7.2)	0.0 (N/A)	0.7 (0, 2.1)
Peru	Tumbes	Rural	210	0.0 (N/A)	1.7 (0.1, 3.3)	0.0 (N/A)	284	0.6 (0, 1.7)	0.9 (0, 2.0)	0.0 (N/A)
Peru	Tumbes	Urban	186	0.0 (N/A)	1.5 (0, 3.2)	0.0 (N/A)	304	0.0 (N/A)	1.4 (0.1, 2.7)	0.0 (N/A)

eGFR=estimated glomerular filtration rate; <sup>a</sup> age-standardised prevalence using WHO global population age weights; <sup>b</sup> includes race adjustment; <sup>c</sup> not available as eGFR values supplied and exact age not available; N/A=no CI available due to zero estimate

## Appendix

### The DEGREE Study Group

Wichai Aekplakorn, Ramathibodi Hospital, Thailand

Shuchi Anand, Stanford University, USA

Aurora Aragón, Wuqu' Kawoq Maya Health Alliance, Guatemala

Antonio Bernabe-Ortiz, Universidad Peruana Cayetano Heredia, Peru

Annibale Biggeri, University of Padua, Italy

Emmanuel Burdmann, Sao Paulo University, Brazil

Ben Caplin, University College London, UK

Dolores Catelan, University of Padua, Italy

Pubudu Chulasiri, Ministry of Health, Sri Lanka

Philip Cooper, St George's University of London, UK; International University of Ecuador, Ecuador

Ricardo Correa-Rotter, National Autonomous University of Mexico, Mexico

Sandra Cortés, Pontifical Catholic University of Chile, Chile

Amelia Crampin, Malawi Epidemiology and Intervention Research Unit (MEIRU), Malawi; University of Glasgow, Scotland

Melissa de Santiago, Johns Hopkins Bloomberg School of Public Health, USA

Meghnath Dhimal, Nepal Health Research Council, Nepal

Chiara Doccioli, University of Florence, Italy

Prabhakaran Dorairaj, Public Health Foundation of India, India

Samuel Dorevitch, University of Illinois Chicago, Kenya

Catterina Ferreccio, Pontifical Catholic University of Chile, Chile

Jason Glaser, La Isla Network, USA

Marvin Gonzalez-Quiroz, The University of Texas Health Science Centre at San Antonio, USA; Wuqu' Kawoq Maya Health Alliance, Guatemala; University College London, UK

Emily Granadillo, International University of Ecuador, Ecuador

Monsermin Gualan, International University of Ecuador, Ecuador

Balaji Gummidi, George Institute, India

Nalika Gunawardena, WHO, India

Sophie Hamilton, UK Health Security Agency, UK

Michelle Hathaway, University of Illinois Chicago, Kenya

Kristina Jakobsson, University of Gothenburg, Sweden

Prashant Jarhyan, Public Health Foundation of India, India

Vivekanand Jha, George Institute, India



Oomen John, George Institute, India  
Richard J Johnson, Colorado University, USA  
Prabhdeep Kaur, Indian Institute of Science, India  
Chagriya Kitiyakara, Ramathibodi Hospital, Thailand  
Pornpimol Kongtip, Mahdiol University, Thailand  
Hans Kromhout, Utrecht University, Netherlands  
Adeera Levin, University of British Columbia, Canada  
Magdalena Madero, Ignacio Chavez Institute, Mexico  
Estelle McLean, London School of Hygiene and Tropical Medicine, UK  
J. Jaime Miranda, Universidad Peruana Cayetano Heredia, Peru  
Joseph Mkandawire, Malawi Epidemiology and Intervention Research Unit (MEIRU), Malawi  
Sailesh Mohan, Public Health Foundation of India, India  
Sharan Murali, Indian Council of Medical Research - National Institute of Epidemiology (ICMR-NIE), India  
Devaki Nair, University College London; Health Service Laboratory, UK  
Wisdom Nakanga, Malawi Epidemiology and Intervention Research Unit (MEIRU), Malawi  
Dorothea Nitsch, London School of Hygiene and Tropical Medicine, UK  
Mary Njoroge, London School of Hygiene and Tropical Medicine, UK  
Moffat Nyirenda, Medical Research Council/Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine Uganda Research Unit, Uganda; Malawi Epidemiology and Intervention Research Unit (MEIRU), Malawi  
Cristina O'Callaghan-Gordo, Open University of Catalonia, Spain; ISGlobal, Spain; Pompeu Fabra University, Spain; Epidemiology and Public Health area of the Red Biomedical Research Centre (CIBERESP), Spain  
Neil Pearce, London School of Hygiene and Tropical Medicine, UK  
Anil Poudyal, Nepal Health Research Council, Nepal  
Narayan Prasad, Sanjay Gandhi Post Graduate Institute of Medical Sciences, India  
Lesliam Quirós-Alcalá, Johns Hopkins Bloomberg School of Public Health, USA  
Giuseppe Remuzzi, Istituto Mario Negri, Italy  
Steven Robertson, London School of Hygiene and Tropical Medicine, UK  
Peter Rohloff, Wuqu' Kawoq Maya Health Alliance, Guatemala  
Natalia Romero-Sandoval, International University of Ecuador, Ecuador  
Andrea Ruiz-Alejos, Universidad Peruana Cayetano Heredia, Peru  
Charlotte Rutter, London School of Hygiene and Tropical Medicine, UK  
Thilanga Ruwanpathirana, Ministry of Health, Sri Lanka  
Manikandanesan Sakthivel, Indian Council of Medical Research, India  
Rajiv Saran, University of Michigan, USA

Sameera Senanayake, Duke-NUS Medical School, Singapore

Leah Shaw, Wuqu' Kawoq Maya Health Alliance, Guatemala

Ajay Singh, Harvard University, USA

Liam Smeeth, London School of Hygiene and Tropical Medicine, UK

Camilo Sotomayor, Universidad de Chile, Chile

Ravi Raju Tatapudi, The Apollo University, India

Eva Tuiz, Wuqu' Kawoq Maya Health Alliance, Guatemala

Nikhil Srinivasapura Venkateshmurthy, Public Health Foundation of India, India

Vidhya Venugopal, Sri Ramachandra Institute of Higher Education and Research, India

SC Wickramasinghe, Ministry of Health, Sri Lanka

Journal Pre-proof

